IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Active, not recruiting · Phase 1, Phase 2 · NCT04086264
Conditions: Acute Myeloid Leukemia
At a glance
- Research payments reported, 2025
- $575,040
- U.S. investigators named
- 8
- Sites paid
- 8
- Planned or actual enrollment
- 218
About the trial
- Sponsor
- AbbVie
- Tested
- Azacitidine (drug), IMGN632 (drug), Venetoclax (drug)
- Dates
- Started 2019-11-06; completion 2027-02
- Results posted
- Not yet
This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in participants with relapsed and frontline CD123-positive AML.
From ClinicalTrials.gov, last updated 2025-08-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $575,040 in research payments for this study in 2025 (53 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Deepa Jeyakumar, M.D. Hematology & Oncology · Orange, CA
- David A. Sallman, M.D. Hematology & Oncology · Tampa, FL
- Patrick W. Burke, M.D. Hematology · Ann Arbor, MI
- Kebede H. Begna, M.D. Hematology · Rochester, MN
- Eunice Wang, MD Hematology & Oncology · Buffalo, NY
- Catherine Lai, M.D., M.P.H. Hematology & Oncology · Philadelphia, PA
- Naval G. Daver, MBBS Hematology & Oncology · Houston, TX
- Roland B. Walter, MD PHD Hematology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Moffitt Cancer Center $291,673
- Uci Health-Orange, CA $193,717
- Ut MD Anderson Cancer Center $64,764
- Mayo Clinic Rochester $11,100
- Fred Hutchinson Cancer Research Center $6,320
- Hospital of Univ of Pennsylvania, PA $4,379
- University of Michigan Health System, MI $2,275
- Health Research Inc Roswell PArk Division $812
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.